Cluenex
Log inStart free
All stocks · Industrials · Government Services

Maximus MMS

Maximus scores average on business quality (4.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$59.39Oct 9, 2026
Business qualityAverage
Next earningsNov 18, 2026
Insiders, 90 daysQuiet

Why it matters

  1. What Maximus does

    Maximus operates government health and human services programs, administering benefits like Medicaid and Medicare for public agencies. It generates revenue through long-term outsourcing contracts with federal, state, and foreign governments. The company is actively pursuing operational efficiency to expand margins across its core segments.

  2. What it does best

    Maximus excels at managing complex government healthcare programs, delivering scale that smaller rivals cannot match. Its return on equity reaches 21.7%, reflecting efficient use of shareholder capital in a specialized market.

  3. The main risk

    Heavy reliance on government contracts exposes Maximus to budget cuts and shifting political priorities. A single major policy shift could impair significant revenue streams.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Gross margin stands at 25.6% with operating margin at 11.0%. Profitability is stable but constrained by labor-heavy service delivery costs, limiting margin expansion at scale.

MoatFair

Long-term government contracts create high switching costs and entrenched public sector relationships. Its return on equity ranks in the top quartile of its sector at 57th percentile.

GrowthSlow

Revenue growth slows at 2.4%, lagging historical top-line expansion. This muted pace highlights a cooling growth engine compared to prior years.

Financial healthFair

Debt-to-equity sits at 0.8 with interest coverage at 6.5x, leaving manageable debt service costs. Free cash flow reached $434 million, pointing to solid cash generation overall.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on MMS

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is MMS a good business?

Maximus scores average on the Cluenex quality check (4.5 of 10), measured against its own industry. Profitability is weak, moat fair, growth slow and financial health fair.

Are insiders buying MMS?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does MMS report earnings?

Nov 18, 2026.

For members

See MMS today

  • Today's verdict on MMS, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Maximus (MMS)”, https://cluenex.com/stocks/mms/, data as of Oct 10, 2026.